JP2024518788A5 - - Google Patents
Info
- Publication number
- JP2024518788A5 JP2024518788A5 JP2023569684A JP2023569684A JP2024518788A5 JP 2024518788 A5 JP2024518788 A5 JP 2024518788A5 JP 2023569684 A JP2023569684 A JP 2023569684A JP 2023569684 A JP2023569684 A JP 2023569684A JP 2024518788 A5 JP2024518788 A5 JP 2024518788A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- oligonucleotide
- bases
- base
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186342P | 2021-05-10 | 2021-05-10 | |
| US63/186,342 | 2021-05-10 | ||
| PCT/US2022/028450 WO2022240795A1 (en) | 2021-05-10 | 2022-05-10 | Compositions targeting sodium channel 1.6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518788A JP2024518788A (ja) | 2024-05-02 |
| JP2024518788A5 true JP2024518788A5 (https=) | 2025-05-19 |
Family
ID=84028798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569684A Pending JP2024518788A (ja) | 2021-05-10 | 2022-05-10 | ナトリウムチャネル１．６を標的とする組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220370487A1 (https=) |
| EP (1) | EP4337772A1 (https=) |
| JP (1) | JP2024518788A (https=) |
| CA (1) | CA3219942A1 (https=) |
| WO (1) | WO2022240795A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112633A1 (en) * | 2003-09-17 | 2005-05-26 | Armour Christopher D. | Alternatively spliced isoforms of sodium channel, voltage gated, type VIII, alpha (SCN8A) |
| US7919472B2 (en) * | 2004-09-17 | 2011-04-05 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| ES2526295T5 (es) * | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| RS61447B1 (sr) * | 2011-04-21 | 2021-03-31 | Glaxo Group Ltd | Modulacija ekspresije virusa hepatitisa b (hbv) |
| WO2015187988A1 (en) * | 2014-06-04 | 2015-12-10 | Intellimedix | Composition and methods of treating epilepsy and/or epilepsy-related disorders |
| CA2958524A1 (en) * | 2014-08-20 | 2016-02-25 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| IL300258A (en) * | 2020-08-07 | 2023-03-01 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating SCN2A |
-
2022
- 2022-05-10 JP JP2023569684A patent/JP2024518788A/ja active Pending
- 2022-05-10 US US17/740,485 patent/US20220370487A1/en active Pending
- 2022-05-10 EP EP22808153.5A patent/EP4337772A1/en active Pending
- 2022-05-10 CA CA3219942A patent/CA3219942A1/en active Pending
- 2022-05-10 WO PCT/US2022/028450 patent/WO2022240795A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7830340B2 (ja) | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 | |
| JP2021533762A5 (https=) | ||
| JP2016522674A5 (https=) | ||
| JP2018516091A5 (https=) | ||
| JP2016521556A5 (https=) | ||
| JP2015523853A5 (https=) | ||
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| IL247600B (en) | Preparations for the modulation of ataxin 2 expression | |
| CN111918968B (zh) | Micro-RNA 22的抑制剂 | |
| JP2009535039A5 (https=) | ||
| KR20200024793A (ko) | 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법 | |
| US20250163419A1 (en) | Therapeutic compositions for treating pain via multiple targets | |
| CA2957618A1 (en) | Inhibitors of myh7b and uses thereof | |
| EP4463553A1 (en) | Advanced rna targeting (arnatar) | |
| JP2023542889A5 (https=) | ||
| JP2024506709A5 (https=) | ||
| CA3211396A1 (en) | Ube3a antisense therapeutics | |
| NZ554277A (en) | Antisense modulation of integrin alpha 4 expression | |
| JP2024518788A5 (https=) | ||
| US20240209377A1 (en) | Therapeutic compositions for treating pain via multiple targets | |
| CN116670276A (zh) | 用于通过多个靶标治疗疼痛的治疗组合物 | |
| US20250277222A1 (en) | Therapeutic compositions for treating pain via multiple targets | |
| US12163132B2 (en) | Gapmer antisense oligonucleotides targeting SARS-CoV-2 for treating COVID 19 | |
| US20250179497A1 (en) | Use of dinucleotide repeat rnas to treat cancer | |
| US20250250570A1 (en) | Translation enhancing nucleic acid compounds: aso coupled translation – upregulation 1 (act-up1) and uses thereof |